Mechanism of action
TB-500 is studied as a synthetic counterpart of thymosin beta-4 (Tβ4), whose central actin-binding motif (LKKTETQ) sequesters monomeric G-actin and thereby regulates actin polymerization dynamics in the cytoskeleton. In preclinical models this actin interaction is associated with increased migration of endothelial cells, keratinocytes and fibroblasts into injured tissue. Downstream, the literature describes activation of the ILK-PI3K-Akt survival axis, VEGF-mediated angiogenesis and extracellular-matrix remodeling via matrix metalloproteinases (MMPs), together with dampening of NF-κB-dependent inflammatory signaling. In the adult mouse heart, Tβ4 has additionally been linked to activation of quiescent Wt1-positive epicardial progenitor cells after myocardial injury (Smart et al., Nature 2011). These pathway-level observations derive from cell culture and animal models and do not establish any therapeutic effect.
State of evidence
The evidence base is dominated by preclinical work. In-vitro studies characterize the actin-sequestering function of Tβ4; animal models describe accelerated dermal wound closure and, after experimental myocardial infarction in mice, activation of epicardial progenitor cells (Treadwell et al. 2012; Smart et al. 2011). Early human data exist only for pharmaceutical-grade Tβ4 itself: a randomized, placebo-controlled phase 1 single- and multiple-dose study of intravenous Tβ4 (RGN-352) in healthy volunteers assessed safety and pharmacokinetics (Ruff et al. 2010), and small wound-healing studies in patients with pressure or venous ulcers have been reported. Phase 3 trials so far exist only for a topical Tβ4 eye-drop formulation (RGN-259) in neurotrophic keratopathy and dry eye; the published neurotrophic-keratopathy trial enrolled 18 patients and narrowly missed its primary endpoint (Sosne et al. 2023). For systemically administered Tβ4 or TB-500 no phase 3 data exist, and no medicines authority has approved Tβ4 or TB-500 for any indication. TB-500 as a research chemical has not itself undergone clinical development; in analytical chemistry it appears mainly as a doping-control target (Ho et al. 2012). Whether the preclinical findings translate to humans is unresolved; efficacy and safety are not established.
Storage and handling
General handling rules for lyophilized peptides apply: store cool, dry and protected from light. After reconstitution, peptide solutions are kept refrigerated in laboratory practice and used within a few days; repeated freeze-thaw cycles are generally avoided.
Questions about the research
- What is TB-500 investigated for in research?
- TB-500, or thymosin beta-4, is investigated mainly in preclinical models of wound healing, cell migration, angiogenesis and cardiac repair. The focus is the peptide's actin-binding function, which cell-culture and animal studies associate with tissue regeneration. TB-500 is additionally a subject of analytical research in doping control.
- What is the state of the evidence on TB-500?
- The data are predominantly preclinical: in-vitro work and animal models of skin and cardiac tissue. For pharmaceutical-grade Tβ4 there is one phase 1 study in healthy volunteers, small early wound-healing studies and phase 3 trials of a topical eye-drop formulation that did not meet their primary endpoints; for systemic use no phase 3 data exist, and there are no regulatory approvals. Efficacy and safety in humans are not established.
Sources
- Bock-Marquette et al., Nature 2004 (ILK/PI3K-Akt axis)DOI: 10.1038/nature03000PMID: 15565145
- Treadwell et al., Ann N Y Acad Sci 2012DOI: 10.1111/j.1749-6632.2012.06717.xPMID: 23050815
- Smart et al., Nature 2011DOI: 10.1038/nature10188PMID: 21654746
- Ruff et al., Ann N Y Acad Sci 2010DOI: 10.1111/j.1749-6632.2010.05474.xPMID: 20536472
- Sosne et al., Int J Mol Sci 2023DOI: 10.3390/ijms24010554PMID: 36613994
- Ho et al., J Chromatogr A 2012DOI: 10.1016/j.chroma.2012.09.043PMID: 23084823